7SJS image
Entry Detail
PDB ID:
7SJS
Keywords:
Title:
Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40.8
Biological Source:
PDB Version:
Deposition Date:
2021-10-18
Release Date:
2022-01-12
Method Details:
Experimental Method:
Resolution:
1.61 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 2 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:stem helix peptide of Spike protein S2'
Chain IDs:C
Chain Length:25
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:CC40.8 Fab heavy chain
Chain IDs:A (auth: H)
Chain Length:217
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:CC40.8 Fab light chain
Chain IDs:B (auth: L)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.
Sci Transl Med 14 eabi9215 eabi9215 (2022)
PMID: 35133175 DOI: 10.1126/scitranslmed.abi9215

Abstact

Broadly neutralizing antibodies (bnAbs) to coronaviruses (CoVs) are valuable in their own right as prophylactic and therapeutic reagents to treat diverse CoVs and as templates for rational pan-CoV vaccine design. We recently described a bnAb, CC40.8, from a CoV disease 2019 (COVID-19) convalescent donor that exhibits broad reactivity with human β-CoVs. Here, we showed that CC40.8 targets the conserved S2 stem helix region of the CoV spike fusion machinery. We determined a crystal structure of CC40.8 Fab with a SARS-CoV-2 S2 stem peptide at 1.6-Å resolution and found that the peptide adopted a mainly helical structure. Conserved residues in β-CoVs interacted with CC40.8 antibody, thereby providing a molecular basis for its broad reactivity. CC40.8 exhibited in vivo protective efficacy against SARS-CoV-2 challenge in two animal models. In both models, CC40.8-treated animals exhibited less weight loss and reduced lung viral titers compared to controls. Furthermore, we noted that CC40.8-like bnAbs are relatively rare in human COVID-19 infection, and therefore, their elicitation may require rational structure-based vaccine design strategies. Overall, our study describes a target on β-CoV spike proteins for protective antibodies that may facilitate the development of pan-β-CoV vaccines.

Legend

Protein

Chemical

Disease

Primary Citation of related structures